Associations - idarubicin

No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	cytarabine + methotrexate + idarubicin Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin Sensitive : A2	cytarabine + methotrexate + idarubicin Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin Sensitive : A2
NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3
FLT3-ITD mutation + DNMT3A mutation + NRAS mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + DNMT3A mutation + NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
FLT3-ITD mutation + ASXL1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + ASXL1 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
FLT3-ITD mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
DNMT3A mutation + ASXL1 mutation	Acute Myelogenous Leukemia	DNMT3A mutation + ASXL1 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
DNMT3A mutation + NRAS mutation	Acute Myelogenous Leukemia	DNMT3A mutation + NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
NPM1 mutation + SRSF2 mutation	Acute Myelogenous Leukemia	NPM1 mutation + SRSF2 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3
SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3
FLT3 mutation + NRAS mutation	Acute Myelogenous Leukemia	FLT3 mutation + NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
ASXL1 mutation	Acute Myelogenous Leukemia	ASXL1 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
NUP98-PRRX1 fusion	Acute Myelogenous Leukemia	NUP98-PRRX1 fusion	Acute Myelogenous Leukemia	cytarabine + idarubicin Sensitive: C4 – Case Studies cytarabine + idarubicin Sensitive : C4	cytarabine + idarubicin Sensitive: C4 – Case Studies cytarabine + idarubicin Sensitive : C4

idarubicin

Associations
(22)

Associations
(22)

idarubicin

Associations(22)

Associations(22)

Associations
(22)

Associations
(22)